Article Text
Statistics from Altmetric.com
Almost 35 years ago, my colleagues and I first reported a new phenomenon: the decisions of many freshly enrolled research subjects appeared to be based on confusion between the nature of research and of ordinary treatment.1 We called the phenomenon ‘therapeutic misconception’ (TM), and noted that it was characterised by inaccurate beliefs about the degree of individualisation of treatment and likelihood of benefit associated with enrolment in a clinical trial. Since that original paper, dozens of studies from around the world have confirmed the existence of TM and its substantial prevalence, with rates of some degree of TM approaching or exceeding 50% in many studies.2 The concept of TM has become a given in the world of research ethics.
Commonly accepted concepts, of course, are prime targets for academic revisionism, so it is not a surprise to see an article like that by Kim et al in this issue of JME.3 Indeed, Kim et al have embarked on a series of studies aimed at challenging the idea that TM is a major concern in consent to research. This is not the place to comment on the project as a whole, but the study reported here exemplifies its problems. It is based on the notion that “the apparent prevalence of TM indicates [sic] a form of measurement error”, that …
Footnotes
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
↵i In an ongoing study of TM led by my colleague Chuck Lidz, we found that subjects recruited from a list of people who indicated an interest in participating in research in general (n=36), compared with newly recruited subjects from a clinic population (n=55), had significantly higher scores (ie, indicating less TM) on the scale used to measure TM (mean scores 38.1 vs 30.4; analysis of variance F=8.491, df=1, p=0.005).5
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
- Understanding the ‘therapeutic misconception’ from the research participant’s perspective
- Vulnerability, therapeutic misconception and informed consent: is there a need for special treatment of pregnant women in fetus-regarding clinical trials?
- Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
- Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
- Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis
- Occupational exposure and amyotrophic lateral sclerosis in a prospective cohort
- Does the index-to-ring finger length ratio (2D:4D) differ in amyotrophic lateral sclerosis (ALS)? Results from an international online case–control study
- Understanding people’s ‘unrealistic optimism’ about clinical research participation